ABSTRACT
Background Identifying protein biomarkers for chronic obstructive pulmonary disease (COPD) has been challenging. Most previous studies have utilized individual proteins or pre-selected protein panels measured in blood samples. Mass spectrometry proteomic studies of lung tissue have been based on small sample sizes.
Methods We utilized mass spectrometry proteomic approaches to discover protein biomarkers from 150 lung tissue samples representing COPD cases and controls. Top COPD-associated proteins were identified based on multiple linear regression analysis with false discovery rate (FDR) < 0.05. Correlations between pairs of COPD-associated proteins were examined. Machine learning models were also evaluated to identify potential combinations of protein biomarkers related to COPD.
Results We identified 4407 proteins passing quality controls. Twenty-five proteins were significantly associated with COPD at FDR < 0.05, including Interleukin 33, Ferritin (light chain and heavy chain), and two proteins related to caveolae (CAV1 and CAVIN1). Multiple previously reported plasma protein biomarkers for COPD were not significantly associated with proteomic analysis of COPD in lung tissue, although RAGE was borderline significant. Eleven pairs of top significant proteins were highly correlated (r > 0.8), including several strongly correlated with RAGE (EHD2 and CAVIN1). Machine learning models using Random Forests with the top 5% of protein biomarkers demonstrated reasonable accuracy (0.766) and AUC (0.702) for COPD prediction.
Conclusions Mass spectrometry proteomic analysis of lung tissue is a promising approach for the identification of biomarkers for COPD.
Competing Interest Statement
In the past three years, EKS, PJC, and MHC have received grant support from GSK and Bayer. MHC has received speaking or consulting fees from AstraZeneca and Illumina. PJC has received consulting fees from GSK and Novartis. Other authors do not have a financial relationship with a commercial entity that has an interest in the subject of this manuscript.
Funding Statement
The study is supported by NIH grants, including R01 HL133135, R01 HL147148, R01 HL137927, R01 HL124233, R01 GM087221 and P01 HL114501. This study utilized biological specimens and data provided by the Lung Tissue Research Consortium (LTRC) supported by the National Heart, Lung, and Blood Institute (NHLBI).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
the Partners Human Research Committee as the IRB with protocol number 2013P000706/BWH
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Data will be available through the Proteomics Identification Database at EMBL-EBI upon manuscript publication.
